Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239502 | 0.91 | EGFR (0.59) | EGFRKDRERBB2EPHA2EPHB4 | |
| SCHEMBL4578621 | 0.90 | EGFR (0.47) | EGFRKDRERBB2EPHA2EPHB4 | |
| SCHEMBL4578880 | 0.86 | EGFR (0.53) | EGFRKDRERBB2ABCG2 | |
| SCHEMBL4578463 | 0.85 | EGFR (0.62) | EGFRKDRABCG2 | |
| SCHEMBL5097627 | 0.84 | EGFR (0.61) | EGFRKDRERBB2EPHA2EPHB4 | |
| SCHEMBL22983424 | 0.83 | KDR (0.50) | EGFRKDRFLT1ABCG2 | |
| SCHEMBL31472883 | 0.83 | KDR (0.50) | EGFRKDRFLT1ABCG2 | |
| SCHEMBL4577295 | 0.83 | EGFR (0.60) | EGFRKDRABCG2 | |
| SCHEMBL4578873 | 0.83 | EGFR (0.50) | EGFRKDRERBB2EPHA2EPHB4 | |
| SCHEMBL19124251 | 0.83 | EGFR (0.60) | EGFRKDRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| CN-101304978-B | Quinazoline derivative as multi-component inhibitor, pharmaceutical composition and application | HANMI PHARM IND CO LTD | 2012-12-26 | — | — | CN | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| CN-101304978-A | Quinazoline derivatives as multiplex inhibitors and process for their preparation | HANMI PHARM IND CO LTD (KR) | 2008-11-12 | — | — | CN | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | EGFR 955/4885KDR 1226/4885ERBB2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.